Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999675 | 0.95 | ALDH1A1 (0.46) | ALDH1A1HPGDHSD17B10HCAR3HCAR2 | |
| SCHEMBL3005051 | 0.94 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10HCAR2GPR84 | |
| SCHEMBL3005337 | 0.94 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10HCAR2GPR84 | |
| SCHEMBL27788644 | 0.94 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10HCAR2GPR84 | |
| SCHEMBL16058909 | 0.94 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10HCAR2GPR84 | |
| SCHEMBL2999896 | 0.94 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10HCAR2GPR84 | |
| SCHEMBL3007164 | 0.90 | ALDH1A1 (0.37) | ALDH1A1HPGDHSD17B10HCAR2GABRA1 | |
| SCHEMBL28045511 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HPGDHSD17B10PARP1HCAR3 | |
| SCHEMBL3006924 | 0.87 | TBXAS1 (0.40) | ALDH1A1HPGDHSD17B10GPR84TSHR | |
| Acetic Acid SCHEMBL27806863 | 0.87 | PARP1 (0.39) | ALDH1A1HPGDHSD17B10PARP1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103492372-B | Regulate the Carbox amide of androgen receptor | ORION CORP. (FI) | 2015-09-30 | — | — | CN | disclosed |
| CN-103492372-A | Androgen receptor modulating carboxamides | ORION CORP | 2014-01-01 | — | — | CN | disclosed |
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH IP EE B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2167474-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | Valletta Health IP EE B.V. (NL) | 2010-03-31 | — | — | EP | disclosed |
| CN-101679293-A | Urocanic acid derivatives useful for the treatment of immune-related and inflammatory diseases | VALETTA HEALTH B V | 2010-03-24 | — | — | CN | disclosed |
| WO-2008153385-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | VALLETTA HEALTH B.V. (NL) | 2008-12-18 | — | — | WO | disclosed |
| US-5929249-A | ANGIOTENSIN II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| US-5728842-A | ANGIOTENSIN II RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0653937-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0653937-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994000120-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197752-A1 | UROCANIC ACID DERIVATIVES USEFUL FOR THE TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES | UTS2R, UACA, HCAR1 | ALDH1A1 2060/4885HPGD 685/4885HSD17B10 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.